Life Biosciences frames the intraocular injection as a step toward reversing aging itself. The gap between treating one disease of aging and treating aging as a whole is the real story.
Life Biosciences has dosed its first human volunteer, a person with glaucoma, with a reprogramming therapy injected directly into the eye. The biotech is already framing the milestone as a step toward reversing aging itself, not just treating one disease of the eye.
The treatment, delivered by intravitreal injection, is called ER-100 and is designed to regenerate retinal ganglion cells — the optic nerve cells that glaucoma slowly erodes — using Life Biosciences' Epigenetic Restoration platform. The company announced the first participant was dosed on June 9, 2026, marking the first clinical candidate from the platform to reach human testing. The trial is registered on ClinicalTrials.gov as NCT07290244.
The broader pitch, delivered through the same announcement, is that a therapy able to rewird eye cells could be retuned for other age-related conditions, and eventually for aging as a whole. MIT Technology Review's Jessica Hamzelou covered the milestone in The Checkup, the publication's biotech vertical, noting that David Sinclair, the company's co-founder and a Harvard professor of genetics, has already said he plans to test an oral reprogramming drug as part of a $101 million XPrize competition.
The science Life Biosciences is betting on is called cellular reprogramming. The idea is to take an adult cell and nudge it toward a younger state by switching on a small set of genes — in this case, three of the four Yamanaka factors: OCT4, SOX2, and KLF4 (OSK). The press release specifies OSK without MYC, and describes the approach as controlled expression to reset the epigenetic code to more youthful patterns of gene expression, rather than full reprogramming to a pluripotent stem cell state. That distinction is the central safety bet: used in full, Yamanaka factors can erase a cell's identity and create tumors; the newer strategy exposes adult cells to the factors briefly and in a controlled way, nudging them younger without erasing what they are. Preclinical studies, according to the company, demonstrated improved tissue performance and restored visual function in animal models. The eye trial — for open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION) — is designed to test whether that bet holds in humans.
The eye is a sensible proving ground for that bet, and not only because that is the disease Life Biosciences chose to chase. The eye is immune-privileged, meaning the immune system is more permissive of foreign biological material there than in most organs, which lowers the bar for delivering a gene-therapy payload. The anatomy is accessible, so injection is straightforward. And the outcome is measurable: clinicians can image the optic nerve, test visual fields, and track changes over months. If partial reprogramming helps, or harms, it should show up there in ways that are harder to see in, say, the liver or the brain.
The leap Life Biosciences is making, though, is much bigger than glaucoma. The company frames the platform as a potential route to other age-related diseases and, longer-term, to reversing aging itself. That is a different claim from regenerating a damaged optic nerve, and the distance between the two is the real test of the technology. The reprogramming field carries a serious safety history: tumorigenicity risk from the Yamanaka factors, loss of cell identity when the dose is wrong, and a long list of failures in animal models. The eye is small enough and observable enough to make those risks manageable to study, but it is also narrow enough that "we treated glaucoma" is a long way from "we reversed aging." The Phase 1 trial will evaluate safety and tolerability as its primary endpoints, with additional endpoints assessing visual function.
What to watch next: the first safety readout, particularly for inflammation, unintended dedifferentiation, or tumor signals; whether the same platform moves into a second indication; and whether the company's broader anti-aging thesis — including Sinclair's planned oral reprogramming drug — advances in parallel. The eye is the bet. Aging is the pitch. Between those two points lies most of the work.